Promoting Health through Vitamin D Therapeutics

Improving People's Lives by Treating and Preventing the Clinical Consequences of
Vitamin D Insufficiency and Secondary Hyperparathyroidism


Recent News:

FDA Accepts OPKO's New Drug Application for Rayaldee™
July 28, 2015

OPKO Announces Submission of Rayaldee™ New Drug Application to U.S. Food and Drug Administration
May 29, 2015

Phase 3 Data Supporting Rayaldee™ As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at NKF 2015 Spring Clinical Meetings
March 27, 2015



© 2015 OPKO Health Inc.- All rights reserved. | Privacy Policy | Terms Of Use